Aridis Receives Agreement from the European Medicines Agency on the Clinical Study Design and a Single Confirmatory Phase 3 Study of AR-301
ARDSDelisted Stock | USD 0.27 0.02 8.00% |
Slightly above 55% of Aridis Pharmaceuticals' private investors are presently thinking to get in. The analysis of overall sentiment of trading Aridis Pharmaceuticals pink sheet suggests that some investors are interested at this time. Aridis Pharmaceuticals' investing sentiment can be driven by a variety of factors including economic data, Aridis Pharmaceuticals' earnings reports, geopolitical events, and overall market trends.
Aridis Pharmaceuticals pink sheet news, alerts, and headlines are usually related to its technical, predictive, social, and fundamental indicators. It can reflect on the current distribution of Aridis daily returns and investor perception about the current price of Aridis Pharmaceuticals as well as its diversification or hedging effects on your existing portfolios.
Aridis |
LOS GATOS, Calif., July 17, 2023 Aridis Pharmaceuticals, Inc. today announced positive feedback from the European Medicines Agency on the Companys proposed single confirmatory Phase 3 study of investigational monoclonal antibody candidate AR-301, which is being developed as an adjunctive therapy in combination with standard of care antibiotics for the treatment of pneumonia caused by Gram-positive bacteria Staphylococcus aureus in mecha
Read at finance.yahoo.com
Aridis Pharmaceuticals Fundamental Analysis
We analyze Aridis Pharmaceuticals' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Aridis Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Aridis Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Number Of Employees
Number Of Employees Comparative Analysis
Aridis Pharmaceuticals is currently under evaluation in number of employees category among its peers. Number of Employees shows the total number of permanent full time and part time employees working for a given company and processed through its payroll.
Aridis Pharmaceuticals Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Aridis Pharmaceuticals pink sheet to make a market-neutral strategy. Peer analysis of Aridis Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Aridis Pharmaceuticals by comparing valuation metrics with similar companies.
Peers
Aridis Pharmaceuticals Related Equities
RVPH | Reviva Pharmaceuticals | 8.77 | ||||
AKTX | Akari Therapeutics | 8.04 | ||||
ADTX | Aditxt | 6.06 | ||||
ATXI | Avenue Therapeutics | 4.37 | ||||
ABVC | ABVC Biopharma | 3.92 | ||||
RNAZ | Transcode Therapeutics | 2.94 | ||||
DRMA | Dermata Therapeutics | 2.73 | ||||
KOD | Kodiak Sciences | 1.83 | ||||
UNCY | Unicycive Therapeutics | 1.47 | ||||
REVB | Revelation Biosciences | 1.33 | ||||
HOTH | Hoth Therapeutics | 1.20 | ||||
NRBO | Neurobo Pharmaceuticals | 0.43 | ||||
CGTX | Cognition Therapeutics | 2.44 | ||||
ZVSA | ZyVersa Therapeutics | 3.60 | ||||
RVPHW | Reviva Pharmaceuticals | 4.35 | ||||
VRAX | Virax Biolabs | 4.83 |
Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in unemployment. You can also try the Insider Screener module to find insiders across different sectors to evaluate their impact on performance.
Other Consideration for investing in Aridis Pink Sheet
If you are still planning to invest in Aridis Pharmaceuticals check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Aridis Pharmaceuticals' history and understand the potential risks before investing.
Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios | |
Equity Valuation Check real value of public entities based on technical and fundamental data | |
Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
Price Ceiling Movement Calculate and plot Price Ceiling Movement for different equity instruments | |
Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios | |
Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency | |
Performance Analysis Check effects of mean-variance optimization against your current asset allocation | |
Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk | |
Content Syndication Quickly integrate customizable finance content to your own investment portal |